Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain
Open Access
- 1 January 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 80 (1) , 18-29
Abstract
Spinal cord stimulators (SCSs) are neuromodulation devices implanted in the epidural space with the goal of treating chronic pain that fails to respond to conventional treatment. SCSs have been increasingly used in recent years1,2; approximately 50 000 are implanted annually in the US3 at a cost of approximately $3.5 billion.4 Some have advocated for greater use of SCSs to reduce risks of medications, including opioids and gabapentinoids.5Keywords
This publication has 34 references indexed in Scilit:
- Sham Controls in Medical Device TrialsNew England Journal of Medicine, 2014
- State of the Field Survey: Spinal Cord Stimulator Use by Academic Pain Medicine PracticesPain Medicine, 2013
- Spinal Cord Stimulation as Treatment for Complex Regional Pain Syndrome Should Be Considered Earlier Than Last Resort TherapyNeuromodulation: Technology at the Neural Interface, 2013
- Costs and Cost-Effectiveness of Spinal Cord Stimulation (SCS) for Failed Back Surgery SyndromeSpine, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Spinal cord stimulation for failed back surgery syndrome: Outcomes in a workers’ compensation settingPain, 2010
- De Facto Long-term Opioid Therapy for Noncancer PainThe Clinical Journal of Pain, 2008
- Back Pain Prevalence and Visit RatesSpine, 2006
- Lumbar Disc Disorders and Low-Back Pain: Socioeconomic Factors and ConsequencesJournal of Bone and Joint Surgery, 2006
- The cost effectiveness of spinal cord stimulation in the treatment of pain: a systematic review of the literatureJournal of Pain and Symptom Management, 2004